The expert anglers at Milliken Fishing reflect on a dream day catching double-digit bass and the techniques that made it possible. Fears are brewing over an oil-price shock that could rattle markets ...

When we design a microcontroller (MCU) project, we normally leave a few port lines unused, so that last-minute requirements can be met. Invariably, even those lines also get utilized as the project ...

We recently published 11 Stocks on Jim Cramer’s Radar. JPMorgan Chase & Co. (NYSE:JPM) is one of the stocks on Jim Cramer radar. Banking giant JPMorgan Chase & Co. (NYSE:JPM) crossed Jim Cramer’s ...

He's set to make $9 million in 2026 and $10 million in 2027. If they pick up his 2028 option, he'll make $7 million. The buyout for that option is $4 million, guaranteeing him at least $23 million. If ...

ORLANDO, Fla. – Steven Matz, who spent the second half of the ’25 season in the Red Sox bullpen, has a two-year deal with their division-rival Tampa Bay Rays, pending a physical. The veteran ...

Multiple homes are damaged after a tornado touched down near Houston, Texas, on Monday afternoon, officials said. Mark Herman, Harris County Constable for Precinct Four, said deputies are responding ...

Apple, Amazon, Lockheed Martin, Microsoft, Google, Coinbase, Comcast and Meta are just some of the major companies who have made donations to build President Donald Trump’s proposed 90,000-square-foot ...

Unity Software is rated a buy, positioned at an inflection point for double-digit growth, driven by its CS and GS segments and the Vector launch. U's new Vector AI ad platform is a game-changer, ...

With the international break upon us, there is some inevitable chat about transfers despite January still being a few months away. CaughtOffside report that the Blues are still looking to buy a ...

Micron Technology Inc (NASDAQ:MU) can potentially generate substantially higher earnings ahead, driven by multiple quarters of double-digit price hikes, according to Morgan Stanley. The Micron ...

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple myeloma trial. But with the study continuing to evaluate the other primary ...